TG Therapeutics published five year data from the Phase 3 ULTIMATE I & II open label extension studies of BRIUMVI in relapsing multiple sclerosis. The dataset covers thousands of patient years and ...
Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study finds.
Real-world data show Ocrevus reduced relapse rates and maintained disability stability in relapsing MS over four years.
Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...
DelveInsight’s 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple ...
WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing ...
SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...
Please provide your email address to receive an email when new articles are posted on . A phase 2 study included 129 individuals with MS randomized to receive frexalimab or placebo for 24 weeks.
Symptoms and frequency of relapses vary widely from person to person with the most common form of multiple sclerosis — and doctors aren’t entirely sure why. But, what exactly does a relapse look like?
Disability accumulation may occur independently of relapses for some patients in the early phase of relapsing-remitting multiple sclerosis (MS), according to new research. Approximately 61% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results